CLOs on the Move

Rebus Biosystems

www.rebusbio.com

 
Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rebusbio.com
  • 2255, Martin Avenue
    Santa Clara, CA USA 95050
  • Phone: 408.988.2700

Executives

Name Title Contact Details

Similar Companies

Canadian Light Source

Canadian Light Source is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cerno Bioscience

Cerno Bioscience is a company that develops and publishes mass spectrometry calibration and analysis software that extends the limits of mass spectrometry.

Contrafect

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.

Dewpoint Therapeutics

Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.